The VAD Journal: The journal of mechanical assisted circulation and heart failure

Peer-Reviewed Original Research

Citation: Burchett A.et al. (2017)
“Venoarterial extracorporeal
membrane oxygenation for
cardiogenic shock: a retrospective
analysis based on the etiology of
shock”.
The VAD Journal, 3. doi:
https://doi.org/10.13023/VAD.2017.
04
Editor-in-Chief: Maya Guglin,
University of Kentucky

Venoarterial extracorporeal
membrane oxygenation for
cardiogenic shock: a retrospective
analysis based on the etiology of
shock
Andrew Burchett1*, Thomas Tribble1, Richard Charnigo2, Susan Smyth1,
and Maya Guglin1
1

Division of Cardiovascular Medicine, Gill Heart and Vascular Institute, University
of Kentucky, Lexington, Kentucky.
2

Received: December 15, 2016

Department of Statistics; Department of Biostatistics, University of Kentucky,
Lexington, Kentucky

Accepted: March 16, 2017

*Corresponding author: burchett.andrew@uky.edu

Published: March 16, 2017
© 2017 The Author(s). This is an

open access article published
under the terms of the Creative
Commons AttributionNonCommercial 4.0 International
License
(https://creativecommons.org/licens
es/by-nc/4.0/), which permits
unrestricted non-commercial use,
distribution, and reproduction in
any medium, provided that the
original author(s) and the publication
source are credited.

Funding: Not applicable
Competing interests: Not applicable

Abstract
Background
We performed a retrospective analysis to evaluate the efficacy of VA-ECMO
support in cardiogenic shock based on various etiologies.
Methods
We retrospectively analyzed 99 patients supported with VA-ECMO from January 1,
2012 to January 1, 2015. Outcomes included survival to discontinuation of VAECMO support and survival to hospital discharge. The etiologies of cardiogenic
shock included cardiac arrest (CPR), acute myocardial infarction (AMI),
decompensated congestive heart failure (CHF), pulmonary embolism (PE), right
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ventricular failure (RVF) not secondary to an acute pulmonary embolism, and postcardiotomy syndrome (PCS). The PCS group was used as a reference group;
odds ratios were estimated and Fisher’s exact tests were performed to compare
each other group to the reference.
Results
Patients supported with VA-ECMO due to PE and CHF had better survival to
hospital discharge (83.3% and 54.2%, with p = 0.003 and p = 0.011, respectively)
versus the PCS group (7.7%). The PE, CHF, and AMI groups had statistically
improved survival to VA-ECMO discontinuation. There was no statistically
significant difference in survival to VA-ECMO discontinuation or hospital discharge
in four subgroup analyses.
Conclusions
Patients supported with VA-ECMO in cardiogenic shock due to PE or CHF
demonstrated increased rates of survival to hospital discharge when compared to
the PCS group. This study also highlights the need for a more uniform system of
categorizing etiologies of cardiogenic shock.
Keywords: Venoarterial extracorporeal membrane oxygenation, refractory
cardiogenic shock, heart failure, pulmonary embolism, mechanical circulatory
support

Introduction
Extracorporeal membrane oxygenation (ECMO), also known as extracorporeal life
support (ECLS), has been available as a life-saving means of supporting
respiratory or cardiac function since the 1970’s. 1,2 The first successful use of
venoarterial ECMO (VA-ECMO) was reported in 1972.3 The first successful use of
ECMO for treatment of cardiogenic shock was in 1973. 4 However, during this era
there was no proven survival advantage over conventional management, largely
due to high complication rates.1,2 There has been a renewed interest in the use of
ECMO for cardiopulmonary disease 5,6, mostly due to technological advances,
improved risk-benefit profile6-9, and increasing evidence and experience. 5,6
ECMO is an invasive technique that allows for the oxygenation of deoxygenated
blood. Deoxygenated blood is drained from the venous system, pumped through
an oxygenator, and then re-infused to the patient. This allows for the exchange of
carbon dioxide and oxygen. Veno-venous ECMO (VV-ECMO) can be used to
bypass the lung and oxygenate blood when only respiratory support is
necessary.10 VA-ECMO bypasses both the heart and lungs, and thus can be
utilized to provide both circulatory and respiratory support to patients with
significantly impaired cardiac function, with or without impaired gas exchange. 11
The primary goal of this analysis was to evaluate the efficacy of VA-ECMO support
for cardiogenic shock based on the underlying etiology, and to identify patient
populations that derive the most benefit from VA-ECMO support. Outcomes
evaluated included survival to VA-ECMO decannulation and survival to hospital
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discharge. In addition, we evaluated these outcomes in the following subgroups:
cardiogenic shock due to primarily right ventricular failure vs. primarily left
ventricular failure, peripheral vs. central VA-ECMO access site, VA-ECMO
cannulation performed by cardiothoracic surgery (CTS) vs. interventional
cardiology, and post-cannulation management by either the cardiology critical care
service vs. other critical care services.

Methods
Following institutional review board approval, data were collected by a combination
of chart review of our institution’s electronic medical record and data collected by
the members of the mechanical circulatory support (MCS) team. Cases in which
only VV-ECMO was used were excluded. For individual patients who were
cannulated multiple times during one admission, each cannulation was counted as
one initiation of VA-ECMO. Data regarding date of death were obtained via our
institution’s inpatient and outpatient medical records, as well as an internet search
of the Social Security Death Index and obituaries.
All patients were thought to be in cardiogenic shock as a primary indication for VAECMO initiation. Distinguishing the etiology of cardiogenic shock proved difficult
because it was very common for patients to have multiple pathologic processes
contributing to shock. We defined the following groups for etiologies of cardiogenic
shock: cardiac arrest and subsequent cardiopulmonary resuscitation (CPR), acute
myocardial infarction (AMI), decompensated congestive heart failure (CHF), acute
pulmonary embolism (PE), right ventricular failure (RVF) not secondary to an acute
pulmonary embolism, and post-cardiotomy syndrome (PCS).
The patients in the CPR group were found to be in cardiogenic shock post cardiac
arrest or with ongoing CPR. The cardiac arrest event for each patient was
secondary to a variety of primary etiologies, including but not limited to AMI, PE,
hypoxic respiratory failure, RVF, primary arrhythmia, and PCS. The patients in the
AMI group were thought to have had an acute coronary thrombosis resulting in
either a ST segment elevation myocardial infarction (STEMI) or non-ST segment
elevation myocardial infarction (NSTEMI) with subsequent cardiogenic shock. The
patients in the CHF group had varying etiologies of decompensated heart failure.
The majority of this group had known severe, acute on chronic CHF. This group
also included less frequent etiologies of acute decompensated heart failure such
as peripartum cardiomyopathy, acute myocarditis, and stress-induced
cardiomyopathy secondary to a pheochromocytoma. The patients in the PCS
group underwent CTS for a variety of reasons. The majority of these patients
developed cardiogenic shock following coronary artery bypass grafting (CABG) or
valvular surgery, and failed weaning from cardiopulmonary bypass in the operating
room. Some of these patients had undergone cardiac surgery for less frequent
reasons such as carcinoid syndrome with valvular involvement or orthotropic heart
transplant. The PE group included patients that were in cardiogenic shock
secondary to acute, massive PE. The RVF group included patients with pulmonary
conditions ranging from primary arterial pulmonary hypertension to pulmonary
hypertension secondary to interstitial lung disease, but did not include patients with
acute PE.
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For survival to decannulation, each episode of VA-ECMO cannulation was used,
resulting in 106 events for analysis. For survival to hospital discharge the number
of individual patients was used, resulting in 99 events. Because some individual
patients were placed on VA-ECMO multiple times for different etiologies of
cardiogenic shock, the sum total of individuals cannulated for each etiology of
cardiogenic shock was 102 as opposed to 99.
Historically, PCS was the most common indication for the utilization of VA-ECMO.
The Nationwide Inpatient Sample database reports that the PCS group comprised
80% of all ECMO utilizations, and that cardiogenic shock comprised 16% in 1998.
In 2009, 40% of ECMO initiations were due to PCS and 39% were due to
cardiogenic shock.12 Comprising the PCS group of all patients who failed weaning
from cardiopulmonary bypass in the perioperative setting is consistent with other
similar retrospective analyses.11,13,14 Because PCS is historically the most common
indication for VA-ECMO initiation, and this group had the lowest rate of survival to
decannulation and hospital discharge, the PCS group (n = 13) was used as a
reference group for calculating estimated odds ratios (OR) and accompanying
95% confidence intervals (CI). This method has been used by Carrol et al. in a
similar retrospective analyses.14 Fisher’s exact test was used to acquire p-values.
When the necessary information was available in the electronic medical record, we
further analyzed survival by separating occurrences of VA-ECMO into subgroups:
cardiogenic shock due to primarily left ventricular failure vs. primarily right
ventricular failure; peripheral vs. central access for VA-ECMO; VA-ECMO initiation
performed by either CTS vs. an interventional cardiologist; and primary
management post-cannulation by either the critical care cardiology service vs.
other services.
The six main groups were compared on age and gender using one-way analysis of
variance and a version of Fisher’s exact test for larger contingency tables,
respectively.
A p-value less than 0.05 was regarded as statistically significant. Data analysis
was performed using Excel 2013 and SAS Version 9.3.

Results
Between January 1, 2012, and January 1, 2015, VA-ECMO was initiated to
provide support for cardiogenic shock in 99 patients on 106 occasions at our
institution. Of these 99 individual patients, 67 (67.7%) were male and 32 (32.3%)
were female. The mean +SD age was 51.3 ±14.9 years. The groups with the
lowest mean age were the CHF and RVF groups, with mean ages of
approximately 49 years. The groups with the highest mean age were the AMI and
PE groups, with mean ages of approximately 57 years. However, the variation in
mean ages across groups was not significant (p = 0.527). All groups were in their
majority male, with the exception of the PE group, which was evenly divided in
gender. The variation in gender ratios across groups was not significant (p =
0.597). The baseline characteristics are summarized in Table 1.
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Table 1. Baseline characteristics: mean age and gender for each group.
Mean Age (SD)

Male (%)

Female (%)

Total

51.3 (14.9)

67 (67.7%)

32 (32.3%)

CPR

49.8 (15.1)

25 (78.1%)

7 (21.9%)

AMI

57.4 (10.8)

8 (72.7%)

3 (27.3%)

CHF

48.8 (15.9)

16 (66.7%)

8 (33.3%)

PE

56.5 (13.8)

3 (50.0%)

3 (50.0%)

RVF

48.5 (14.6)

9 (56.3%)

7 (43.8%)

PCS

53.3 (18.0)

9 (69.2%)

4 (30.8%)

Note: Some persons belonged to more than one group. Within each row, however, each
person is counted only once.

Results regarding rates of survival to ECMO discontinuation and survival to
hospital discharge are furnished in Table 2 and Table 3, respectively.
Table 2. Survival to decannulation, using post-cardiotomy syndrome as the
reference group
Total # Cannulations

Survived to Decannulation

OR (survival)

p-value

(95% CI)

OR (dying)

N

%

N

%

(95% CI)

Total

106

100.0%

55

51.9%

CPR

32

30.2%

12

37.5%

2.00 (0.46-8.74)

0.492

0.50 (0.11-2.19)

AMI

13

12.3%

9

69.2%

7.50 (1.31-43.0)

0.047

0.13 (0.02-0.76)

CHF

26

24.5%

20

76.9%

11.1 (2.29-54.0)

0.002

0.09 (0.02-0.44)

PE

6

5.7%

5

83.3%

16.7 (1.36-204.0)

0.041

0.06 (0.05-0.73)

RVF

16

15.1%

6

37.5%

2.00 (0.39-10.3)

0.454

0.50 (0.10-2.58)

PCS

13

12.3%

3

23.1%

1.00 (reference)

1.00 (reference)

Note: OR = estimated odds ratio, CI = confidence interval.
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Table 3. Survival to hospital discharge, using post-cardiotomy syndrome as
the reference group
# Individuals Cannulated

Survived to Discharge

OR (survival)

p-value

(95% CI)

OR (dying)

N

%

N

%

(95% CI)

Total

99

100.0%

36

36.4%

CPR

32

32.3%

9

28.1%

4.70 (0.53-41.6)

0.238

0.21 (0.02-1.89)

AMI

11

11.1%

5

45.5%

10.0 (0.94-105.9)

0.061

0.10 (0.01-1.06)

CHF

24

24.2%

13

54.2%

14.18 (1.58-127.0)

0.011

0.07 (0.01-0.63)

PE

6

6.1%

5

83.3%

60.0 (3.10-1160)

0.003

0.02 (0.001-0.32)

RVF

16

16.2%

4

25.0%

4.00 (0.39-41.2)

0.343

0.25 (0.02-2.58)

PCS

13

13.1%

1

7.7%

1.00 (reference)

1.00 (reference)

Note: Some persons belonged to more than one group. Within each row, however, each
person is counted only once. OR = estimated odds ratio, CI = confidence interval.

For the 106 occurrences of VA-ECMO initiation, survival to weaning of VA-ECMO
support occurred on 55 (51.9%) occasions. Survival to hospital discharge occurred
for 36 of the 99 (36.4%) individual patients.
For the PCS group (the reference group) survival to ECMO decannulation
occurred in three of the 13 events (23.1%) of ECMO initiation. Only one of the 13
(7.7%) patients initiated on VA-ECMO survived to hospital discharge.
The AMI, CHF, and PE groups had significantly higher rates of survival to ECMO
decannulation than the reference group. For the 13 initiations of VA-ECMO in the
AMI group, nine (69.2%) survived to ECMO decannulation (p = 0.047). For the 26
initiations in the CHF group, 20 (76.9%) survived (p = 0.002). For the six initiations
in the PE group, five (83.3%) survived (p = 0.041).
The CHF and PE groups had significantly higher rates of survival to hospital
discharge than the reference group. For the CHF group, 13 of the 24 (54.2%)
individuals supported with VA-ECMO survived to hospital discharge (p = 0.011).
For the PE group, five of six (83.3%) individuals survived (p = 0.003). Of note, all
patients in the PE group who survived to ECMO decannulation survived to hospital
discharge.
Additional analyses were performed to evaluate other factors in relation to survival
to VA-ECMO decannulation and survival to hospital discharge. These factors
included whether the patient was in cardiogenic shock due to primarily left
ventricular failure vs. primarily right ventricular failure, central vs. peripheral VAECMO access, VA-ECMO cannulation performed by CTS vs. interventional
cardiology, and post-cannulation management by the cardiovascular critical care
team vs. a different inpatient service. There was no significant difference in
survival to ECMO discontinuation or survival to hospital discharge between any of
these groups. The results appear in Table 4 and Table 5.
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Table 4. Subgroup analysis of survival to VA-ECMO discontinuation
Total #
Cannulations

Survived to Decannulation

OR Survival

(n, %)

(95%, CI)

LV Failure

70

37

52.9%

1.35 (0.59-3.09)

RV Failure

33

15

45.5%

1.00 (reference)

Peripheral

74

36

48.6%

0.63 (0.27-1.49)

Central

30

18

60.0%

1.00 (reference)

CTS

91

44

48.4%

0.47 (0.15-1.48)

Interventional
Cardiology
CCU

15

10

66.7%

1.00 (reference)

41

20

48.8%

0.92 (0.42-2.02)

Other

65

33

50.8%

1.00 (reference)

p-value

OR Death (95%, CI)

0.531

0.74 (0.32-1.71)
1.00 (reference)

0.387

1.58 (0.67-3.75)
1.00 (reference)

0.266

2.14 (0.68-6.74)
1.00 (reference)

1.000

1.08 (0.5-2.37)
1.00 (reference)

Note: OR = estimated odds ratio, CI = confidence interval.

Table 5. Subgroup analysis of survival to hospital discharge
# Individuals
Cannulated

Survived to Discharge

OR Survival

(n, %)

(95%, CI)

pvalue

OR Death (95%,
CI)

0.507

1.37 (0.57-3.27)

LV Failure

66

22

33.3%

0.73 (0.31-1.75)

RV Failure

32

13

40.6%

1.00 (reference)

Peripheral

71

25

35.2%

0.72 (0.30-1.77)

Central

28

12

42.9%

1.00 (reference)

CTS

85

28

32.9%

0.43 (0.14-1.31)

Interventional
Cardiology

15

8

53.3%

1.00 (reference)

CCU

39

14

35.9%

0.95 (0.41-2.18)

Other

62

23

37.1%

1.00 (reference)

1.00 (reference)
0.497

1.38 (0.57-3.37)
1.00 (reference)

0.152

2.33 (0.77-7.06)
1.00 (reference)

1.000

1.05 (0.46-2.42)
1.00 (reference)

Note: Some persons belonged to more than one group. Within each row, however, each
person is counted only once. OR = estimated odds ratio, CI = confidence interval.
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Discussion
In a retrospective analysis of patients with cardiogenic shock placed on VA-ECMO
we found that there were 106 events in 99 individual patients, 36.4% of which
survived to hospital discharge.
Survival to VA-ECMO decannulation was better in the AMI, CHF, and PE groups
when compared to the PCS group. Also, more patients with CHF and PE survived
to discharge.
There were no statistically significant survival differences in patients in cardiogenic
shock due to primarily left ventricular failure vs. right ventricular failure, central
ECMO cannulation vs. peripheral ECMO cannulation, ECMO cannulation
performed by CTS vs. interventional cardiology, or post-cannulation management
by the cardiology critical care service vs. other inpatient services.
This retrospective analysis was performed to identify patient populations that may
derive greater benefit from VA-ECMO as a means of providing MCS for patients in
cardiogenic shock. We grouped patients supported by VA-ECMO by the
underlying etiology of cardiogenic shock to compare rates of survival to VA-ECMO
discontinuation and survival to hospital discharge.
Data demonstrating the efficacy of VA-ECMO support in the setting of cardiogenic
shock largely comes from retrospective analyses such as this. 14-17 There is
considerable variability in the documentation of the etiologies of cardiogenic shock
in the VA-ECMO literature.15 For example, in the Extracorporeal Life Support
Organization (ELSO) ECLS Registry Report from January 2015, patients placed
on ECLS for cardiac causes were grouped into the following categories: congenital
defect, cardiac arrest, cardiogenic shock, cardiomyopathy, myocarditis, and other.
In this system, more patients were included in the “other” group (1,785) than all
other groups combined (1,621).18 Because of this variability, it is difficult to
evaluate the efficacy of VA-ECMO in the setting of cardiogenic shock across
different institutions. To better evaluate the efficacy of VA-ECMO in cardiogenic
shock due to specific pathological processes, a more uniform system to categorize
patients in cardiogenic shock is necessary.
Our grouping system consisting of CPR, AMI, CHF, RVF, PE, and PCS is efficient
and intuitive, both separating clinically different etiologies of cardiogenic shock and
representing the vast majority of patients in cardiogenic shock. The benefit of such
a system is that these specific etiologies of cardiogenic shock differ in their
pathophysiology, management, and prognosis. Carroll et al. used a similar system
with the following etiologies: AMI, PE, acute cardiomyopathy, chronic
cardiomyopathy, post-cardiotomy shock, or other. In this system, patients that
suffered cardiac arrest were placed into a group based on the underlying
pathologic process causing cardiac arrest, and placed in the “other” group if no
underlying process was identified.14
Patients who undergo CPR create difficulty with regard to classification. The ECLS
registry defines extracorporeal membrane oxygenation for adults in cardiac arrest
(eCPR) as the following: “extracorporeal life support (ECLS) used as part of initial
resuscitation from cardiac arrest. Patients who are hemodynamically unstable and
placed on ECLS without cardiac arrest are not considered E-CPR”.18
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These patients typically undergo CPR due to a variety of underlying pathologic
processes, such as AMI and PE. However, the fact that they suffer from cardiac
arrest generally worsens their prognosis. In addition, these patients may not be in
cardiogenic shock until they undergo cardiac arrest. Therefore, we assigned them
their own group in our classification system. However, an argument can be made
that these patients should be grouped based on the etiology of cardiac arrest.
Also, there may be benefit in further dividing patients in the CHF group into
patients with acute on chronic CHF and patients with acute decompensated CHF
with no history of cardiomyopathy. Examples of patients that would fit in the latter
division include those suffering from fulminant myocarditis or peripartum
cardiomyopathy. Acutely decompensated CHF patients with no history of
cardiomyopathy may be more likely to have a better prognosis due to potential
reversibility, which may result in increased benefit to temporary support with VAECMO.
This analysis has limitations. It is retrospective as opposed to a prospective
randomized controlled trial. However, the decision to initiate VA-ECMO support in
these cases occurred in emergent situations, and in general VA-ECMO is initiated
because patients are deemed to be at great risk of not surviving without it. The
emergent nature of VA-ECMO initiation makes it difficult to propose a prospective
randomized controlled trial, necessitating retrospective analyses which would
benefit from a more uniform system of documentation across institutions.
Another limitation is the relatively small number of patients in some of the
cardiogenic shock etiology groups, even though the total of 99 patients supported
with VA-ECMO over a three-year period is a substantial number for a single
institution. The fact that survival to VA-ECMO decannulation and hospital
discharge in the PE group was found to be significantly better than in the reference
group, notwithstanding the small sample size in the PE group, highlights the
effectiveness of VA-ECMO in this setting. In addition, the relatively small numbers
of patients in some groups demonstrates the need for increased uniformity across
institutions, so that data may be pooled for meta-analysis.
Even with its limitations, this analysis provides valuable data regarding patients
supported with VA-ECMO in cardiogenic shock. In particular, it demonstrates
significantly increased rates of survival to hospital discharge in the CHF and PE
groups versus PCS patients. In addition, we have proposed a classification system
that can be used across institutions, so that larger numbers of patients can be
pooled for meta-analysis to gain a better understanding of the efficacy of VAECMO use for specific etiologies of cardiogenic shock.

Conclusions
In patients with cardiogenic shock and supported with VA-ECMO, the PCS group
had the worst prognosis, with only 7.7% surviving to discharge. Patients with CHF
and PE have the best prognosis, with 54.2% and 83.3% surviving to discharge,
respectively. Prognosis was especially favorable for PE, where everyone who
survived to decannulation was discharged alive. Our analysis underscores the
need for functional, intuitive, and uniform classification of indications for VA
ECMO.
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